HFIZG53 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HFIZG53 polypeptides and polynucleotides in the design of protocols for the trea tment of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasi s, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency dis orders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Par kinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failur e, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign pr ostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic de pression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's diseas e or Gilles dela Tourett's syndrome, among others, and diagnostic assays for such conditions.
HFIZG53